AcelRx shareholders approve reverse stock split of 1-for-10 to 1-for-30

TALPHERA, INC.

Special meeting held Sep 23, 2022; proposal to authorize board to effect reverse split passed.
Common shares: 53,371,108 for, 25,270,193 against; plus Series A Preferred votes included proportionally.
Board authorized to implement split at ratio from 1:10 to 1:30 within one year.
No broker non-votes; proposal was approved.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.